Overview

Kristine completed her PhD in Tumour Immunology & Virology at the University of Queensland, focusing on the development of a fully human monoclonal antibody to the Epstein-Barr virus. Her research led to her postdoctoral career at the QIMR Berghofer Medical Research Institute, where she successfully developed Ebvizumab, a novel antibody that could neutralise Epstein-Barr virus infection both in vitro and in vivo. Her work on Ebvizumab led to her patent where she is named an inventor on the PCT application. Kristine also has experience in the Business Development sector, where she worked as an intern consulting researchers and establishing partnerships with international pharmaceutical companies.

Kristine is currently training to be a patent attorney with the Chemical & Life Sciences team at Spruson & Ferguson, and completing her master’s degree in Intellectual Property Law at University of Technology Sydney.